Oncode Accelerator Secures €123M to Revolutionize Personalized Cancer Therapy Development

Oncode Accelerator is thrilled to announce a groundbreaking funding milestone, having raised €123,000,000 to further their mission of collaboratively optimizing and accelerating the development of new cancer therapies for patients of all ages.

This significant investment underscores the strong confidence in Oncode Accelerator’s innovative approach, where state-of-the-art technologies, patient data integration, and artificial intelligence converge at the earliest stages of preclinical therapy development.

By harnessing tools such as patient-derived organoid models, Oncode Accelerator is uniquely positioned to drive the development of oncology-targeted therapeutics across four dynamic pipelines: small molecules, biologics, cell and gene therapies, and therapeutic vaccines.

The newly raised funds will empower the company to expand its Demonstrator Projects, which make their world-class, integrated toolbox accessible to researchers globally.

These projects are designed to turn validated hits into valuable clinical candidates, ensuring that promising targets can rapidly advance into effective, personalized cancer treatments.

As part of a vibrant public-private partnership backed by the Dutch National Growth Fund (NGF), Oncode Accelerator brings together key institutions including Leiden University, Leiden University Medical Center, the Netherlands Cancer Institute, Princess Máxima Center, UMC Utrecht, and the Oncode Accelerator Foundation.

This collaborative network reinforces a shared dedication to outsmart cancer and drive meaningful impact on lives worldwide.

With the substantial infusion of capital, the company is poised to not only accelerate scientific discovery but also redefine the landscape of cancer therapy development, bringing us one critical step closer to transforming patient care and ultimately overcoming cancer.